Racial differences in time from prostate cancer diagnosis to treatment initiation: A Population-Based Study

Cancer

Volumn 119, Issue 13, 2013, Pages 2486-2493

  Stokes, William A ^a   Hendrix, Laura H ^a   Royce, Trevor J ^a   Allen, Ian M ^a   Godley, Paul A ^a,b   Wang, Andrew Z ^a,b   Chen, Ronald C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

prostate cancer; racial disparities; treatment delay

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CAUCASIAN; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; THERAPY DELAY;

AFRICAN AMERICANS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTHCARE DISPARITIES; HUMANS; MALE; MEDICARE; MULTIVARIATE ANALYSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEER PROGRAM; TIME-TO-TREATMENT; UNITED STATES;

EID: 84879111100     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27975     Document Type: Article

References (29)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Howlader N, Noone AM, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012. http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER Web site, April 2012.
3. Gilligan T,. Social disparities and prostate cancer: mapping the gaps in our knowledge. Cancer Causes Control. 2005; 16: 45-53.
4. Jones BA, Liu WL, Araujo AB, et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2825-2834.
5. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF,. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004; 64: 1171-1176.
6. Gross CP, Smith BD, Wolf E, Andersen M,. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008; 112: 900-908.
7. Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006; 106: 1276-1285.
8. Institute of Medicine. Crossing the Quality Chasm: Washington, DC: National Academies Press; 2001.
9. Moul JW, Leon S, Amling CL, et al. How long can radical prostatectomy (RP) safely be delayed? CPDR's experiences from 3324 cases. J Urol. 2004; 171 (suppl): 312.
10. Nguyen PL, Whittington R, Koo S, et al. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer. 2005; 103: 2053-2059.
11. Freedland SJ, Kane CJ, Amling CL, et al. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol. 2006; 175: 1298-1302.
12. O'Brien D, Loeb S, Carvalhal GF, et al. Delay of surgery in men with low risk prostate cancer. J Urol. 2011; 185: 2143-2147.
13. National Cancer Institute. Overview of the SEER Program. http://seer.cancer.gov/about/overview.html.
14. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D,. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17: 584-590.
15. Chen RC, Bainbridge J, Carpenter WR, et al. Racial differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer (CaP): a population-based study. J Clin Oncol. 2010; 28 (15 suppl): abstract 9002.
16. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974.
17. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104: 125-132.
18. Bañez LL, Terris MK, Aronson WJ, et al. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?-Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1208-1212.
19. Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ,. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003; 21: 555-563.
20. Lee CT, Madii R, Daignault S, et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 2006; 175: 1262-1267.
21. Do V, Gebski V, Barton MB,. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol. 2000; 57: 131-136.
22. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993; 11: 336-344.
23. Etzioni R, Berry KM, Legler JM, Shaw P,. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology. 2002; 59: 251-255.
24. Spencer BA, Babey SH, Etzioni DA, et al. A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma. Cancer. 2006; 106: 765-774.
25. Oakley-Girvan I, Kolonel LN, Gallagher RP, Wu AH, Felberg A, Whittemore AS,. Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health. 2003; 93: 1753-1759.
26. Mullins CD, Onukwugha E, Bikov K, Seal B, Hussain A,. Health disparities in staging of SEER-medicare prostate cancer patients in the United States. Urology. 2010; 76: 566-572.
27. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA,. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010; 28: 1069-1074.
28. Underwood W, Jackson J, Wei JT, et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer. 2005; 103: 538-545.
29. Hamilton RJ, Aronson WJ, Presti JC, et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer. 2007; 110: 2202-2209.